---
title: CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias
date: '2024-07-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38976877/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240709183440&v=2.18.0.post9+e462414
source: Blood
description: Fusion oncogenes can be cancer-defining molecular alterations that are
  essential for diagnosis and therapy selection.1,2 Rapid and accessible molecular
  diagnostics for fusion-driven leukemias such as acute promyelocytic leukemia (APL),
  Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and chronic
  myeloid leukemia (CML) are unavailable, creating a barrier to timely diagnosis and
  effective targeted therapy in many healthcare settings, including community hospitals
  ...
disable_comments: true
---
Fusion oncogenes can be cancer-defining molecular alterations that are essential for diagnosis and therapy selection.1,2 Rapid and accessible molecular diagnostics for fusion-driven leukemias such as acute promyelocytic leukemia (APL), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and chronic myeloid leukemia (CML) are unavailable, creating a barrier to timely diagnosis and effective targeted therapy in many healthcare settings, including community hospitals ...